ArticleMaterials today. Bio2025
FMRP silencing via siRNA lipid nanoparticles to reprogram the tumor microenvironment and enhance anti-PD-1 efficacy in triple-negative breast cancer.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- CD13 identifies S100A4Biology direct · 2026Article
- Extracellular vesicle-mediated GALNT1/RPRD1A glycosylation axis drives immune escape and peritoneal metastasis in gastric cancer.Journal of experimental & clinical cancer research : CR · 2026Article
- Cholesterol analogs modulate lipid nanoparticle performance for mRNA delivery after lyophilization and enable ocular disease therapy.Materials today. Bio · 2026Article
- Progress of siRNA Nanomedicines in Modulating the Microenvironment of Triple-Negative Breast Cancer.International journal of nanomedicine · 2026Review
- CUL5-mediated ubiquitination in cancer cell therapy: context-dependent roles, molecular networks, and emerging therapeutic avenues.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fragile X mental retardation protein (FMRP), encoded by the Fmr1 gene, is notably upregulated in various malignancies, including triple-negative breast cancer, pancreatic ductal adenocarcinoma, and colon carcinoma, and potentially mediates immune evasion through multiple mechanisms. Here a small interfering RNA (siRNA) targeting Fmr1 is designed for tumor site delivery to suppress FMRP expression and enhance immune activation. Lipid nanoparticles loaded with siFmr1 (LNP@siFmr1) are prepared using a microfluidic-based electrospray method, achieving optimal particle size, encapsulation efficiency, and stability. In an orthotopic breast cancer mouse model, LNP@siFmr1 demonstrates effective passive targeting of tumor sites, leading to significant downregulation of FMRP expression. This suppression coincides with the recruitment and activation of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.